Cargando…
Real-World Epidemiology, Clinical and Economic Burden of Chronic Hepatitis B in Japan: A Retrospective Study Using JMDC Claims Database
INTRODUCTION: Chronic hepatitis B (CHB) is one of the world's major healthcare problems, especially in the Western Pacific regions. This study describes the prevalence, incidence, treatment profiles and clinical and economic burden of chronic hepatitis B patients in Japan using the Japan Medica...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229495/ https://www.ncbi.nlm.nih.gov/pubmed/37067724 http://dx.doi.org/10.1007/s40121-023-00795-0 |
_version_ | 1785051268638572544 |
---|---|
author | Umemura, Takeji Wattanakamolkul, Kittima Nakayama, Yoshikazu Takahashi, Yasushi Sbarigia, Urbano KyungHwa, Lim Villasis-Keever, Angelina Furegato, Martina Gautier, Laurène Nowacki, Gregoire Azzi, Jessica Wu, David Bin-Chia |
author_facet | Umemura, Takeji Wattanakamolkul, Kittima Nakayama, Yoshikazu Takahashi, Yasushi Sbarigia, Urbano KyungHwa, Lim Villasis-Keever, Angelina Furegato, Martina Gautier, Laurène Nowacki, Gregoire Azzi, Jessica Wu, David Bin-Chia |
author_sort | Umemura, Takeji |
collection | PubMed |
description | INTRODUCTION: Chronic hepatitis B (CHB) is one of the world's major healthcare problems, especially in the Western Pacific regions. This study describes the prevalence, incidence, treatment profiles and clinical and economic burden of chronic hepatitis B patients in Japan using the Japan Medical Data Center (JMDC) Claims Database. METHODS: This is a retrospective observational study. Prevalence cases were identified as patients with ≥ 1 inpatient or ≥ 2 outpatient CHB diagnoses and ≥ 2 records for hepatitis B tests or ≥ 1 prescription for CHB treatment between January 2010 and December 2019. Newly diagnosed CHB patients were defined as patients diagnosed from 2010 to 2018 with no history of the disease up to 2 years prior to the diagnosis. The index date is defined as the first CHB diagnosis day. We only used patients’ data with ≥ 1-year post-index date. RESULTS: We identified 13,061 CHB prevalent cases (2010–2019), yielding a crude period prevalence of 0.32%. Newly diagnosed CHB patients (n = 1973; median age 52 years) were followed for a median period of 3.1 years, during which 15% received a CHB treatment. Entecavir was the most common first treatment (66%). During this period, 3.4% of the patients developed compensated cirrhosis (CC), 1.5% decompensated cirrhosis (DC) and 3.0% hepatocellular carcinoma (HCC). Around 43.3% of CHB patients were hospitalized at least once. Hospitalizations, treatment rates, serologic testing and screening for liver diseases increased as the severity of the disease progressed. The average total healthcare cost was 870,568 JPY (7779 USD) per person per year. DC and HCC resulted in the highest management costs. CONCLUSIONS: Chronic hepatitis B represents a high clinical and economic burden for patients and caregivers, given its morbidity and associated costs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-023-00795-0. |
format | Online Article Text |
id | pubmed-10229495 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-102294952023-06-01 Real-World Epidemiology, Clinical and Economic Burden of Chronic Hepatitis B in Japan: A Retrospective Study Using JMDC Claims Database Umemura, Takeji Wattanakamolkul, Kittima Nakayama, Yoshikazu Takahashi, Yasushi Sbarigia, Urbano KyungHwa, Lim Villasis-Keever, Angelina Furegato, Martina Gautier, Laurène Nowacki, Gregoire Azzi, Jessica Wu, David Bin-Chia Infect Dis Ther Original Research INTRODUCTION: Chronic hepatitis B (CHB) is one of the world's major healthcare problems, especially in the Western Pacific regions. This study describes the prevalence, incidence, treatment profiles and clinical and economic burden of chronic hepatitis B patients in Japan using the Japan Medical Data Center (JMDC) Claims Database. METHODS: This is a retrospective observational study. Prevalence cases were identified as patients with ≥ 1 inpatient or ≥ 2 outpatient CHB diagnoses and ≥ 2 records for hepatitis B tests or ≥ 1 prescription for CHB treatment between January 2010 and December 2019. Newly diagnosed CHB patients were defined as patients diagnosed from 2010 to 2018 with no history of the disease up to 2 years prior to the diagnosis. The index date is defined as the first CHB diagnosis day. We only used patients’ data with ≥ 1-year post-index date. RESULTS: We identified 13,061 CHB prevalent cases (2010–2019), yielding a crude period prevalence of 0.32%. Newly diagnosed CHB patients (n = 1973; median age 52 years) were followed for a median period of 3.1 years, during which 15% received a CHB treatment. Entecavir was the most common first treatment (66%). During this period, 3.4% of the patients developed compensated cirrhosis (CC), 1.5% decompensated cirrhosis (DC) and 3.0% hepatocellular carcinoma (HCC). Around 43.3% of CHB patients were hospitalized at least once. Hospitalizations, treatment rates, serologic testing and screening for liver diseases increased as the severity of the disease progressed. The average total healthcare cost was 870,568 JPY (7779 USD) per person per year. DC and HCC resulted in the highest management costs. CONCLUSIONS: Chronic hepatitis B represents a high clinical and economic burden for patients and caregivers, given its morbidity and associated costs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-023-00795-0. Springer Healthcare 2023-04-17 2023-05 /pmc/articles/PMC10229495/ /pubmed/37067724 http://dx.doi.org/10.1007/s40121-023-00795-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Umemura, Takeji Wattanakamolkul, Kittima Nakayama, Yoshikazu Takahashi, Yasushi Sbarigia, Urbano KyungHwa, Lim Villasis-Keever, Angelina Furegato, Martina Gautier, Laurène Nowacki, Gregoire Azzi, Jessica Wu, David Bin-Chia Real-World Epidemiology, Clinical and Economic Burden of Chronic Hepatitis B in Japan: A Retrospective Study Using JMDC Claims Database |
title | Real-World Epidemiology, Clinical and Economic Burden of Chronic Hepatitis B in Japan: A Retrospective Study Using JMDC Claims Database |
title_full | Real-World Epidemiology, Clinical and Economic Burden of Chronic Hepatitis B in Japan: A Retrospective Study Using JMDC Claims Database |
title_fullStr | Real-World Epidemiology, Clinical and Economic Burden of Chronic Hepatitis B in Japan: A Retrospective Study Using JMDC Claims Database |
title_full_unstemmed | Real-World Epidemiology, Clinical and Economic Burden of Chronic Hepatitis B in Japan: A Retrospective Study Using JMDC Claims Database |
title_short | Real-World Epidemiology, Clinical and Economic Burden of Chronic Hepatitis B in Japan: A Retrospective Study Using JMDC Claims Database |
title_sort | real-world epidemiology, clinical and economic burden of chronic hepatitis b in japan: a retrospective study using jmdc claims database |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229495/ https://www.ncbi.nlm.nih.gov/pubmed/37067724 http://dx.doi.org/10.1007/s40121-023-00795-0 |
work_keys_str_mv | AT umemuratakeji realworldepidemiologyclinicalandeconomicburdenofchronichepatitisbinjapanaretrospectivestudyusingjmdcclaimsdatabase AT wattanakamolkulkittima realworldepidemiologyclinicalandeconomicburdenofchronichepatitisbinjapanaretrospectivestudyusingjmdcclaimsdatabase AT nakayamayoshikazu realworldepidemiologyclinicalandeconomicburdenofchronichepatitisbinjapanaretrospectivestudyusingjmdcclaimsdatabase AT takahashiyasushi realworldepidemiologyclinicalandeconomicburdenofchronichepatitisbinjapanaretrospectivestudyusingjmdcclaimsdatabase AT sbarigiaurbano realworldepidemiologyclinicalandeconomicburdenofchronichepatitisbinjapanaretrospectivestudyusingjmdcclaimsdatabase AT kyunghwalim realworldepidemiologyclinicalandeconomicburdenofchronichepatitisbinjapanaretrospectivestudyusingjmdcclaimsdatabase AT villasiskeeverangelina realworldepidemiologyclinicalandeconomicburdenofchronichepatitisbinjapanaretrospectivestudyusingjmdcclaimsdatabase AT furegatomartina realworldepidemiologyclinicalandeconomicburdenofchronichepatitisbinjapanaretrospectivestudyusingjmdcclaimsdatabase AT gautierlaurene realworldepidemiologyclinicalandeconomicburdenofchronichepatitisbinjapanaretrospectivestudyusingjmdcclaimsdatabase AT nowackigregoire realworldepidemiologyclinicalandeconomicburdenofchronichepatitisbinjapanaretrospectivestudyusingjmdcclaimsdatabase AT azzijessica realworldepidemiologyclinicalandeconomicburdenofchronichepatitisbinjapanaretrospectivestudyusingjmdcclaimsdatabase AT wudavidbinchia realworldepidemiologyclinicalandeconomicburdenofchronichepatitisbinjapanaretrospectivestudyusingjmdcclaimsdatabase |